Cancer

Views & Analysis

Changing focus to cachexia may be key to improved cancer out...

Cachexia could be the next blockbuster area in cancer therapeutics because of its link to survival outcomes. Physician and researcher Dr.

News

LAG-3 drugs take centre stage at ASCO, showing potential as ...

LAG-3 drugs from arch-rivals Bristol-Myers Squibb and Merck & Co look set to become talking points at this year's ASCO conference after trial results showed their potential as next-gene

News

Numab raises $110m to develop cancer bispecific antibodies

Switzerland’s Numab has raised 100 million Swiss francs - around $110 million - in Series C financing to develop bispecific antibodies for cancer and inflammation, with Novo Noldings and HB

News

FDA review of Lilly/Innovent's sintilimab paves way for cut-...

The FDA has accepted Eli Lilly and China’s Innovent filing for their latecomer immunotherapy sintilimab, which is expected to compete on price with rivals such as Merck & Co’s Keytruda.

News

BMS agrees deal worth up to $1.56bn for Agenus' TIGIT cancer...

Bristol-Myers Squibb has paid $200 million, and promised up to $1.36 billion in “biobucks” for exclusive rights to a cancer antibody still in the labs of US biotech Agenus, which blocks the

News

AZ/Daiichi unveil data from TNBC hopeful datopotamab deruxte...

AstraZeneca and Daiichi Sankyo have revealed new data from datopotamab deruxtecan in triple negative breast cancer (TNBC) – and although it’s from a small patient group results look impress

Changing focus to cachexia may be key to improved cancer out...

LAG-3 drugs take centre stage at ASCO, showing potential as ...

Numab raises $110m to develop cancer bispecific antibodies

FDA review of Lilly/Innovent's sintilimab paves way for cut-...

BMS agrees deal worth up to $1.56bn for Agenus' TIGIT cancer...

AZ/Daiichi unveil data from TNBC hopeful datopotamab deruxte...

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

Cancer

Editor's Picks